{"id":"https://openalex.org/W2051654271","doi":"https://doi.org/10.1111/j.1528-1157.1986.tb03537.x","title":"Double\u2010Blind Study of Milacemide in Hospitalized Therapy\u2010Resistant Patients With Epilepsy","display_name":"Double\u2010Blind Study of Milacemide in Hospitalized Therapy\u2010Resistant Patients With Epilepsy","publication_year":1986,"publication_date":"1986-06-01","ids":{"openalex":"https://openalex.org/W2051654271","doi":"https://doi.org/10.1111/j.1528-1157.1986.tb03537.x","mag":"2051654271","pmid":"https://pubmed.ncbi.nlm.nih.gov/3516669"},"language":"en","primary_location":{"id":"doi:10.1111/j.1528-1157.1986.tb03537.x","doi":"https://doi.org/10.1111/j.1528-1157.1986.tb03537.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1528-1157.1986.tb03537.x","pdf_url":null,"source":{"id":"https://openalex.org/S203153751","display_name":"Epilepsia","issn_l":"0013-9580","issn":["0013-9580","1528-1157","1528-1167"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084474753","display_name":"M. A. Houtkooper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210161862","display_name":"Stichting Epilepsie Instellingen Nederland","ror":"https://ror.org/051ae7717","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210161862"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"M. A. Houtkooper","raw_affiliation_strings":["Instituut voor Epilepsiebestrijding, Heemstede"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Instituut voor Epilepsiebestrijding, Heemstede","institution_ids":["https://openalex.org/I4210161862"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047261876","display_name":"C. A. E. H. van Oorschot","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. A. E. H. van Oorschot","raw_affiliation_strings":["*Dr. Hans Berger Kliniek, Breda"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*Dr. Hans Berger Kliniek, Breda","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069396241","display_name":"Th.W. Rentmeester","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132398","display_name":"Kempenhaeghe","ror":"https://ror.org/03bbe8e53","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210132398"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"T. W. Rentmeester","raw_affiliation_strings":["\u2020Epilepsiecentrum \u201cKempenhaeghe\u201d, Heeze, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u2020Epilepsiecentrum \u201cKempenhaeghe\u201d, Heeze, The Netherlands","institution_ids":["https://openalex.org/I4210132398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079228655","display_name":"P. J. E. A. H\u00f3ppener","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132398","display_name":"Kempenhaeghe","ror":"https://ror.org/03bbe8e53","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210132398"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"P. J. E. A. H\u00f3ppener","raw_affiliation_strings":["\u2020Epilepsiecentrum \u201cKempenhaeghe\u201d, Heeze, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u2020Epilepsiecentrum \u201cKempenhaeghe\u201d, Heeze, The Netherlands","institution_ids":["https://openalex.org/I4210132398"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068030636","display_name":"Claude Onkelinx","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Onkelinx","raw_affiliation_strings":["\u2021Continental Pharma, Inc., Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u2021Continental Pharma, Inc., Brussels, Belgium","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4360,"currency":"USD","value_usd":4360},"apc_paid":null,"fwci":2.2779,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.86823052,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"27","issue":"3","first_page":"255","last_page":"262"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12267","display_name":"Diet and metabolism studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/milacemide","display_name":"milacemide","score":0.9950000047683716},{"id":"https://openalex.org/keywords/epilepsy","display_name":"epilepsy","score":0.6790000200271606},{"id":"https://openalex.org/keywords/drug-resistant-epilepsy","display_name":"drug-resistant epilepsy","score":0.8309999704360962},{"id":"https://openalex.org/keywords/antiepileptic-efficacy","display_name":"antiepileptic efficacy","score":0.8679999709129333},{"id":"https://openalex.org/keywords/seizure-frequency","display_name":"seizure frequency","score":0.7519999742507935},{"id":"https://openalex.org/keywords/myoclonus-epilepsy","display_name":"myoclonus epilepsy","score":0.8080000281333923},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.9169999957084656},{"id":"https://openalex.org/keywords/blood-brain-barrier","display_name":"blood-brain barrier","score":0.6729999780654907},{"id":"https://openalex.org/keywords/hospitalized-patients","display_name":"hospitalized patients","score":0.6729999780654907},{"id":"https://openalex.org/keywords/young-adults","display_name":"young adults","score":0.6190000176429749}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6794981956481934},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.6187653541564941},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49448609352111816},{"id":"https://openalex.org/C2991744798","wikidata":"https://www.wikidata.org/wiki/Q608510","display_name":"Double blind","level":4,"score":0.43633517622947693},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37504616379737854},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.33855748176574707},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.32566529512405396},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.10179144144058228},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000081","descriptor_name":"Acetamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000081","descriptor_name":"Acetamides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000081","descriptor_name":"Acetamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004351","descriptor_name":"Drug Resistance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004827","descriptor_name":"Epilepsy","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006760","descriptor_name":"Hospitalization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1528-1157.1986.tb03537.x","doi":"https://doi.org/10.1111/j.1528-1157.1986.tb03537.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1528-1157.1986.tb03537.x","pdf_url":null,"source":{"id":"https://openalex.org/S203153751","display_name":"Epilepsia","issn_l":"0013-9580","issn":["0013-9580","1528-1157","1528-1167"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"journal-article"},{"id":"pmid:3516669","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/3516669","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":2,"referenced_works":["https://openalex.org/W1743165899","https://openalex.org/W2086991902"],"related_works":["https://openalex.org/W799980363","https://openalex.org/W2080938563","https://openalex.org/W1984554938","https://openalex.org/W1986703647","https://openalex.org/W1603355437","https://openalex.org/W2088731883","https://openalex.org/W2041067137","https://openalex.org/W1996559567","https://openalex.org/W1989340210","https://openalex.org/W2120725374"],"abstract_inverted_index":{"Summary:":[0],"Milacemide,":[1],"2\u2010N\u2010pentylaminoacetamide,":[2],"a":[3,25,56,126,153,188,261,359,373,384],"glycine":[4],"prodrug,":[5],"which":[6,152],"readily":[7],"crosses":[8],"the":[9,59,63,77,81,85,92,110,122,144],"blood\u2010brain":[10],"barrier,":[11],"has":[12],"been":[13],"tested":[14],"for":[15],"antiepileptic":[16],"efficacy":[17],"and":[18,121],"tol\u2010erability":[19],"in":[20,24,76,84,109,151,157,604,654,727],"30":[21,29,201,208,385,390,608,611],"patients":[22,30,35,47,98,147,202,209,214,227,283,350],"compared":[23],"double\u2010blind":[26],"design":[27],"with":[28,32,65,128,162],"treated":[31],"placebo.":[33,211,304,512],"All":[34,46],"continued":[36],"to":[37,105],"receive,":[38],"without":[39],"alteration,":[40],"their":[41],"previous":[42],"partly":[43],"effective":[44],"medication.":[45],"presented":[48],"an":[49,100],"average":[50],"of":[51,73,96,107,117,125,146],"at":[52],"least":[53],"10":[54,233,442,641],"seizures":[55],"month":[57],"during":[58],"6":[60,239,448,635],"months":[61],"preceding":[62],"trial":[64,78],"no":[66,114,517],"more":[67],"than":[68],"50%":[69,648],"fluctuation.":[70],"The":[71,165],"ratio":[72,251],"seizure":[74,82,158],"frequency":[75,83,159],"period":[79,87],"over":[80],"baseline":[86],"(RSF)":[88],"was":[89,160,167],"calculated.":[90],"In":[91,663],"milacemide":[93,163,361],"group,":[94],"9":[95,282,493,667],"29":[97,108,285,299,496,507,669,678],"had":[99],"RSF":[101],"<0.7":[102,501],"as":[103],"opposed":[104],"2":[106,297,504,676],"placebo":[111],"group.":[112],"Although":[113],"firm":[115],"proof":[116],"therapeutic":[118],"efficacy,":[119],"this":[120],"dramatic":[123],"improvement":[124],"patient":[127,325],"myoclonus":[129],"epilepsy":[130],"indicates":[131],"that":[132],"further":[133],"studies":[134],"are":[135],"warranted.":[136],"This":[137],"opinion":[138,337],"is":[139],"strengthened":[140],"if":[141],"one":[142],"considers":[143],"subgroup":[145],"aged":[148],"\u226425":[149],"years":[150],"statistically":[154],"significant":[155],"reduction":[156],"observed":[161],"treatment.":[164],"drug":[166],"well":[168],"tolerated.":[169],"R\u00c9SUM\u00c9":[170],"La":[171,580],"Milacemide":[172],"(2\u2010n.":[173],"pentylaminoacetamide).":[174],"qui":[175,183,192],"est":[176,338],"une":[177,229,244,311,362],"prodrogue":[178],"de":[179,246,248,252,274,314,317,331,349,352,354,366,404,411,438,468,479,494,505,515,522,558,560,571,574],"la":[180,185,253,258,267,272,318,367,398,402,405,412,416,425,463,466,477,491,523,529,572],"glycine,":[181],"et":[182,197,321],"traverse":[184],"barri\u00e8re":[186],"h\u00e9matoc\u00e9r\u00e9brale":[187],"\u00e9t\u00e9\u00e9tudi\u00e9e":[189],"en":[190,204,294,482,509,533,555],"ce":[191],"concerne":[193],"son":[194],"action":[195],"anti\u00e9pileptique":[196],"sa":[198],"tol\u00e9rance":[199],"chez":[200],"compar\u00e9s":[203],"double":[205],"aveugle":[206],"\u00e0":[207,266],"sous":[210,280,303,360],"Tous":[212,225],"les":[213,226,238],"ont":[215],"continu\u00e9\u00e0":[216],"recevoir":[217],"leur":[218],"m\u00e9dication":[219],"ant\u00e9rieurement":[220],"partiellement":[221],"efficace":[222],"sans":[223],"modification.":[224],"avaient":[228,286],"moyenne":[230],"d'au":[231],"moins":[232,247,353],"crises":[234,256,270],"par":[235,264,340],"mois":[236,240],"pendant":[237,257,271],"pr\u00e9c\u00e9dant":[241],"l'essai":[242],"(avec":[243],"fluctuation":[245],"50%).":[249],"Le":[250,371],"fr\u00e9quence":[254,268,368],"des":[255,269,369],"p\u00e9riode":[259,273],"d'essai":[260],"\u00e9t\u00e9":[262,374],"calcul\u00e9":[263],"rapport":[265],"base":[275],"(r.s.f.).":[276,486],"Dans":[277],"le":[278,301,341,347],"groupe":[279,302],"milacemide,":[281,319],"sur":[284,298],"un":[287,379,436,499,534],"r.s.f.":[288,500,672],"<":[289],"0,7":[290],"alors":[291],"qu'il":[292],"n'y":[293],"avait":[295],"que":[296,330,343,414,428,450,516,540,554],"dans":[300],"Quoique":[305],"ces":[306],"constatations":[307],"ne":[308],"soient":[309,334],"pas":[310],"preuve":[312],"formelle":[313],"l'efficacit\u00e9":[315],"th\u00e9rapeutique":[316],"celles\u2010ci":[320],"l'am\u00e9lioration":[322],"dramatique":[323],"d'un":[324],"atteint":[326],"d'\u00e9pilepsie":[327],"myoclonique,":[328],"indiquent":[329],"nouvelles":[332],"\u00e9tudes":[333],"poursuivies.":[335],"Cette":[336],"fortifi\u00e9e":[339],"fait":[342],"si":[344,551],"l'on":[345],"consid\u00e8re":[346],"sous\u2010groupe":[348],"a\u030cg\u00e9s":[351],"25":[355,561,722],"ans,":[356],"il":[357],"y":[358,387,401,476,528],"r\u00e9duction":[363],"statistiquement":[364],"significative":[365],"crises.":[370],"m\u00e9dicament":[372],"bien":[375,583],"tol\u00e9r\u00e9.":[376],"RESUMEN":[377],"En":[378,487],"estudio":[380],"doble":[381],"ciego":[382],"aplicado":[383],"enfermos":[386,391,422,559],"compar\u00e1ndolos":[388,502],"con":[389,393,455,503,536,578],"tratados":[392],"placebo,":[394],"se":[395,552,565],"ha":[396,461],"estudiado":[397],"eficacia":[399,524],"antiepil\u00e9ptica":[400],"tolerabilidad":[403],"milacemida,":[406,492],"2\u2010n.":[407,587],"pentilaminoacetamida,":[408],"una":[409,519,567],"prodroga":[410],"glicina,":[413],"atraviesa":[415],"barrera":[417],"hematoencef\u00e1lica":[418],"r\u00e1pidamente.":[419],"Todos":[420,432],"los":[421,433,447,469,480,495,506,526],"continuaron":[423],"tomando":[424],"medicaci\u00f3n":[426,581],"previa":[427],"era":[429],"parcialmente":[430],"eficaz.":[431],"sujetos":[434,508],"presentaban":[435],"promedio":[437],"por":[439],"lo":[440],"menos":[441,564],"ataques":[443,470,481,575],"al":[444,452],"mes":[445],"durante":[446,471],"meses":[449],"precedieron":[451],"ensayo":[453,475],"cl\u00ednico":[454],"fluctuaciones":[456],"menores":[457],"del":[458,474],"50%.":[459],"Se":[460],"calculado":[462],"relaci\u00f3n":[464],"entre":[465],"frecuencia":[467,478,573],"el":[472,483,488,510,556],"periodo":[473,484],"basai":[485],"grupo":[489,511],"da":[490],"pacientes":[497],"ten\u00edan":[498],"A":[513],"pesar":[514],"existe":[518],"prueba":[520],"firme":[521],"terap\u00e9utica,":[525],"resultados":[527],"mejor\u00eda":[530],"dram\u00e1tica":[531],"observada":[532],"paciente":[535],"epilepsia":[537],"miocl\u00f3nica,":[538],"sugieren":[539],"otros":[541],"ensayos":[542],"terap\u00e9uticos":[543],"est\u00e1n":[544],"indicados.":[545],"Esta":[546],"opini\u00f3n":[547],"cobra":[548],"m\u00e1s":[549],"importancia":[550],"considera":[553],"subgrupo":[557],"a\u00f1os":[562],"o":[563],"observ\u00f3":[566],"reducci\u00f3n":[568],"estadfsticamente":[569],"significativa":[570],"bajo":[576],"tratamiento":[577],"milacemida.":[579],"fue":[582],"tolerada.":[584],"ZUSAMMENFASSUNG":[585],"Milacemid,":[586],"Pentylaminoacetamid,":[588],"eine":[589,729],"Glycinvorstufe,":[590],"die":[591,593,614,696,715],"rasch":[592],"Bluthirnschranke":[594],"durchdringt,":[595],"wurde":[596,661,742],"auf":[597],"ihre":[598,602,625],"antiepileptische":[599],"Wirksamkeit":[600,690],"und":[601,610,695],"Vertr\u00e4glichkeit":[603],"einem":[605],"Doppelblindversuch":[606],"bei":[607],"Patienten":[609,621,631,670,679,700,718],"weiteren":[612],"Patienten,":[613],"mit":[615,645,701],"Placebo":[616],"behandelt":[617],"wurden,":[618],"untersucht.":[619],"Aile":[620,630],"nahmen":[622],"weiter":[623],"unver\u00e4ndert":[624],"bisherige":[626],"teilweise":[627],"wirkungsvolle":[628],"Medikation.":[629],"zeigten":[632],"w\u00e4hrend":[633],"der":[634,652,655,658,664,680,688,728,733],"vorangegangenen":[636],"Monate":[637],"im":[638,719],"Mittel":[639],"wenigstens":[640],"Anf\u00e4lle":[642],"pro":[643],"Monat":[644],"h\u00f6chstens":[646],"einer":[647],"Fluktuation.":[649],"Das":[650,740],"Verh\u00e4ltnis":[651],"Anfallsfrequenz":[653,734],"Versuchsperiode":[656],"gegen\u00fcber":[657,675],"Basisperiode":[659],"(r.s.f.)":[660],"ermittelt.":[662],"Milacemid\u2010Gruppe":[665],"hatten":[666],"von":[668,673,677,717,721],"einen":[671],"<0,7":[674],"Placebogruppe.":[681],"Obwohl":[682],"das":[683],"Ergebnis":[684,694],"keinen":[685],"sicheren":[686],"Beweis":[687],"therapeutischen":[689],"darstellt,":[691],"bezeugen":[692],"dieses":[693],"dramatische":[697],"Besserung":[698],"eines":[699],"myoklonischer":[702],"Epilepsie,":[703],"da\u00df":[704],"weitere":[705],"Untersuchungen":[706],"w\u00fcnschenswert":[707],"sind.":[708],"Diese":[709],"Meinung":[710],"wird":[711],"bekr\u00e4ftigt,":[712],"wenn":[713],"man":[714],"Untergruppe":[716],"Alter":[720],"Jahren":[723],"oder":[724],"j\u00fcnger":[725],"betrachtet,":[726],"statistisch":[730],"signifikante":[731],"Verminderung":[732],"unter":[735],"Milacemid":[736],"beobachtet":[737],"werden":[738],"konnte.":[739],"Medikament":[741],"gut":[743],"vertragen.":[744]},"counts_by_year":[{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}